Discontinuation of antithrombotic therapy for a year or more in patients with continuous-flow left ventricular assist devices

Naveen Luke Pereira, Dong Chen, Sudhir S. Kushwaha, Soon J. Park

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The recommended anticoagulation regimen during continuous-flow axial left ventricular assist device (LVAD) support is aspirin and warfarin with a targeted international normalized ratio of 2.0-3.0. We report two patients in whom recurrent gastrointestinal bleeding during LVAD support necessitated discontinuation of this anti-thrombotic regimen for a year or more. Despite this, neither patients developed thrombotic complications during 29 patient-months of follow-up. An acquired von Willebrand factor (VWF) abnormality reflected by the absence or decreased abundance of the highest molecular weight multimers was demonstrated in both patients. The gold standard test for platelet function, light transmission platelet aggregometry was measured in one patient and was normal, indicative that the predominant abnormality in the coagulation profile of these patients is an acquired VWF syndrome. Clinical trials are required to address the question whether it is safe to discontinue anticoagulation in LVAD patients with acquired VWF abnormalities.

Original languageEnglish (US)
Pages (from-to)503-505
Number of pages3
JournalInteractive Cardiovascular and Thoracic Surgery
Volume11
Issue number4
DOIs
StatePublished - Oct 2010

Fingerprint

Heart-Assist Devices
von Willebrand Factor
Therapeutics
Platelet Function Tests
International Normalized Ratio
Warfarin
Aspirin
Blood Platelets
Molecular Weight
Clinical Trials
Hemorrhage
Light

Keywords

  • Anticoagulation
  • Gastrointestinal bleeding
  • Heart failure
  • Ventricular assist device

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pulmonary and Respiratory Medicine
  • Surgery

Cite this

Discontinuation of antithrombotic therapy for a year or more in patients with continuous-flow left ventricular assist devices. / Pereira, Naveen Luke; Chen, Dong; Kushwaha, Sudhir S.; Park, Soon J.

In: Interactive Cardiovascular and Thoracic Surgery, Vol. 11, No. 4, 10.2010, p. 503-505.

Research output: Contribution to journalArticle

@article{5c829f74fcda46d0b603e90a7aba8ba9,
title = "Discontinuation of antithrombotic therapy for a year or more in patients with continuous-flow left ventricular assist devices",
abstract = "The recommended anticoagulation regimen during continuous-flow axial left ventricular assist device (LVAD) support is aspirin and warfarin with a targeted international normalized ratio of 2.0-3.0. We report two patients in whom recurrent gastrointestinal bleeding during LVAD support necessitated discontinuation of this anti-thrombotic regimen for a year or more. Despite this, neither patients developed thrombotic complications during 29 patient-months of follow-up. An acquired von Willebrand factor (VWF) abnormality reflected by the absence or decreased abundance of the highest molecular weight multimers was demonstrated in both patients. The gold standard test for platelet function, light transmission platelet aggregometry was measured in one patient and was normal, indicative that the predominant abnormality in the coagulation profile of these patients is an acquired VWF syndrome. Clinical trials are required to address the question whether it is safe to discontinue anticoagulation in LVAD patients with acquired VWF abnormalities.",
keywords = "Anticoagulation, Gastrointestinal bleeding, Heart failure, Ventricular assist device",
author = "Pereira, {Naveen Luke} and Dong Chen and Kushwaha, {Sudhir S.} and Park, {Soon J.}",
year = "2010",
month = "10",
doi = "10.1510/icvts.2010.240747",
language = "English (US)",
volume = "11",
pages = "503--505",
journal = "Interactive Cardiovascular and Thoracic Surgery",
issn = "1569-9293",
publisher = "European Association for Cardio-Thoracic Surgery",
number = "4",

}

TY - JOUR

T1 - Discontinuation of antithrombotic therapy for a year or more in patients with continuous-flow left ventricular assist devices

AU - Pereira, Naveen Luke

AU - Chen, Dong

AU - Kushwaha, Sudhir S.

AU - Park, Soon J.

PY - 2010/10

Y1 - 2010/10

N2 - The recommended anticoagulation regimen during continuous-flow axial left ventricular assist device (LVAD) support is aspirin and warfarin with a targeted international normalized ratio of 2.0-3.0. We report two patients in whom recurrent gastrointestinal bleeding during LVAD support necessitated discontinuation of this anti-thrombotic regimen for a year or more. Despite this, neither patients developed thrombotic complications during 29 patient-months of follow-up. An acquired von Willebrand factor (VWF) abnormality reflected by the absence or decreased abundance of the highest molecular weight multimers was demonstrated in both patients. The gold standard test for platelet function, light transmission platelet aggregometry was measured in one patient and was normal, indicative that the predominant abnormality in the coagulation profile of these patients is an acquired VWF syndrome. Clinical trials are required to address the question whether it is safe to discontinue anticoagulation in LVAD patients with acquired VWF abnormalities.

AB - The recommended anticoagulation regimen during continuous-flow axial left ventricular assist device (LVAD) support is aspirin and warfarin with a targeted international normalized ratio of 2.0-3.0. We report two patients in whom recurrent gastrointestinal bleeding during LVAD support necessitated discontinuation of this anti-thrombotic regimen for a year or more. Despite this, neither patients developed thrombotic complications during 29 patient-months of follow-up. An acquired von Willebrand factor (VWF) abnormality reflected by the absence or decreased abundance of the highest molecular weight multimers was demonstrated in both patients. The gold standard test for platelet function, light transmission platelet aggregometry was measured in one patient and was normal, indicative that the predominant abnormality in the coagulation profile of these patients is an acquired VWF syndrome. Clinical trials are required to address the question whether it is safe to discontinue anticoagulation in LVAD patients with acquired VWF abnormalities.

KW - Anticoagulation

KW - Gastrointestinal bleeding

KW - Heart failure

KW - Ventricular assist device

UR - http://www.scopus.com/inward/record.url?scp=78249233258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78249233258&partnerID=8YFLogxK

U2 - 10.1510/icvts.2010.240747

DO - 10.1510/icvts.2010.240747

M3 - Article

VL - 11

SP - 503

EP - 505

JO - Interactive Cardiovascular and Thoracic Surgery

JF - Interactive Cardiovascular and Thoracic Surgery

SN - 1569-9293

IS - 4

ER -